Phenomenex buys companies in Italy and Denmark

15 April 2007

Phenomenex, a USA-headquartered firm focused in the separation sciences business, has acquired Bologna, Italy-based Chemtek Analytica, a subsidiary of Labservice Analytica, and privately-held SupWare, located in Hilleroed, Denmark.

Both companies were exclusive distributors in their respective territories for chromatography products developed by Phenomenex. Terms of the acquisitions were not disclosed.

Phenomenex is a technology pioneer in research and manufacturing chromatography products used in the separation, analysis and purification of pharmaceuticals, biopharmaceuticals and a broad spectrum of chemicals. With projected 2007 sales exceeding $110.0 million and 465 employees, privately-held Phenomenex has offices in Canada, the UK, Germany, Austria, France, Italy, Denmark, Australia and New Zealand, and also sells its products through a network of partners and distributors in 59 other countries.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight